Related Experiment Video
Updated: Apr 21, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.1K
Antithrombotic therapy: new areas to understand efficacy and bleeding
James W Wisler1, Richard C Becker
1Duke University Medical Center, Division of Cardiology , Durham, NC , USA.
Expert Opinion on Therapeutic Targets
|October 28, 2014
Summary
New antithrombotic therapies aim to inhibit clot formation without increasing bleeding risk. Research identifies novel mediators like neutrophil extracellular traps linking inflammation and thrombosis.
Area of Science:
- Cardiovascular Research
- Hematology
- Pharmacology
Background:
- Antithrombotic therapies face limitations due to bleeding risks.
- Existing treatments link antithrombotic effects with bleeding complications.
Purpose of the Study:
- Review mechanisms of hemostasis and thrombosis.
- Identify novel therapeutic targets to decouple clot formation from bleeding.
- Highlight new agents for pathological thrombus formation.
Main Methods:
- Review of recent developments in understanding hemostasis and thrombosis.
- Analysis of key findings for separating physiological and pathological processes.
- Highlighting novel therapeutic agents targeting identified mechanisms.
Main Results:
- Novel mediators of thrombus formation identified: cell-free nucleic acids, histones, histone-DNA complexes, and neutrophil extracellular traps.
- These mediators link inflammation and thrombosis.
- These mediators may separate physiological hemostasis from pathological thrombosis.
Conclusions:
- Novel therapies targeting identified mediators are under development.
- The goal is to inhibit thrombus formation without increasing bleeding risk.
- Potential to uncouple antithrombotic effects from bleeding complications.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
480
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
480
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:30Venous Thrombosis IV: Nursing Management
405
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
405
01:13Therapeutic Index
7.2K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.2K